When does Transgene report earnings and why does it matter for TNG.PA stock?

Transgene reports on **24 Mar 2026**. The results matter because clinical updates, cash runway commentary and partner milestones can sharply move TNG.PA stock given its low liquidity and high R&D intensity.

What is Meyka AI's short-term forecast for TNG.PA stock?

Meyka AI's short-term monthly forecast is **€0.73**, a modest downside of **-3.18%** versus **€0.754**. This model uses recent price action, fundamentals and sector signals; it is not a guarantee.

What financial metrics should investors watch in the TNG.PA earnings report?

Focus on cash balance, R&D spending, guidance on cash runway, and any milestone payments. Key ratios include EPS **-0.28**, PE **-2.75**, and current ratio **0.54**, which highlight liquidity risk.

How does sector performance affect TNG.PA stock near earnings?

Healthcare and biotech sentiment shapes flows. The European healthcare sector has recently been weak, amplifying negative moves for small biotech names like TNG.PA when trial news is absent or mixed.

EU Stocks

Earnings set 24 Mar: Transgene (TNG.PA) EURONEXT €0.75 intraday, catalyst preview

ByDanny Kontos March 19, 2026

The next earnings release is the immediate risk for TNG.PA stock: Transgene SA (TNG.PA) trades €0.75 intraday on EURONEXT on 19 Mar 2026, down 2.58% today on volume 75,391. Investors will focus on cash runway, R&D spend and clinical updates ahead of results due 24 Mar 2026. Meyka AI’s real-time signals highlight a below-average liquidity profile and a binary biotech risk tied to trial readouts and partner milestones.